Filing Flows › 60 Degrees Pharmaceuticals (SXTP) › Q2 2026
60 Degrees Pharmaceuticals (SXTP) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
60 Degrees Pharmaceuticals (SXTP) reported revenue of $208K for the second quarter 2026 (Q2 2026), +106% from a year earlier and +28% from the quarter before.
60 Degrees Pharmaceuticals, Q2 2026: revenue $208K (+106% year over year), net loss $2.3M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $208K | +28% | +106% |
| Operating profit | −$2.3M | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | −$2.2M | — | — |
What changed
Revenue was $208K in Q2 2026, up 106% year over year and up 28% from the previous quarter.
Gross margin was 27.3%, down 23.1 points from Q2 2025. Operating costs exceeded revenue by $2.3M, an operating margin of -1092.4%. Operating expenses grew 40% against revenue growth of 106%. The quarter ended with a net loss of $2.3M, wider than the previous quarter's $2.1M loss. Minority interests bore $1K of it: to shareholders the quarter was a loss of $2.3M.
Operating cash flow was −$2.2M. Non-cash charges added back $31K of depreciation and amortization and $98K of share-based compensation.
Questions
What was 60 Degrees Pharmaceuticals' revenue in the second quarter 2026?
60 Degrees Pharmaceuticals (SXTP) reported revenue of $208K for the second quarter 2026 (Q2 2026), +106% from a year earlier and +28% from the quarter before.